vs
Fidelis Insurance Holdings Ltd（FIHL）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Fidelis Insurance Holdings Ltd的1.2倍（$772.1M vs $651.9M），Fidelis Insurance Holdings Ltd净利率更高（20.0% vs 12.7%，领先7.3%），Revvity同比增速更快（5.9% vs -5.0%），Revvity自由现金流更多（$161.8M vs $154.6M）
Fidelis Insurance Holdings Ltd是总部位于百慕大的全球特种保险与再保险服务商，提供财产、意外伤害、海事、航空等领域的定制化风险保障方案，服务范围覆盖北美、欧洲等地区的企业及机构客户。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FIHL vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$651.9M
营收增速更快
RVTY
高出10.8%
-5.0%
净利率更高
FIHL
高出7.3%
12.7%
自由现金流更多
RVTY
多$7.2M
$154.6M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $651.9M | $772.1M |
| 净利润 | $130.5M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 24.7% | 14.5% |
| 净利率 | 20.0% | 12.7% |
| 营收同比 | -5.0% | 5.9% |
| 净利润同比 | 29.7% | 3.9% |
| 每股收益（稀释后） | $1.24 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FIHLRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $651.9M | $698.9M | ||
| Q2 25 | $589.3M | $720.3M | ||
| Q1 25 | $658.4M | $664.8M | ||
| Q4 24 | — | $729.4M | ||
| Q3 24 | $686.1M | $684.0M | ||
| Q2 24 | $540.1M | $691.7M | ||
| Q1 24 | $520.0M | $649.9M |
净利润FIHLRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $130.5M | $46.7M | ||
| Q2 25 | $19.7M | $53.9M | ||
| Q1 25 | $-42.5M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $100.6M | $94.4M | ||
| Q2 24 | $53.7M | $55.4M | ||
| Q1 24 | $81.2M | $26.0M |
毛利率FIHLRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率FIHLRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 24.7% | 11.7% | ||
| Q2 25 | 3.8% | 12.6% | ||
| Q1 25 | -7.6% | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | 17.2% | 14.3% | ||
| Q2 24 | 11.6% | 12.4% | ||
| Q1 24 | 18.3% | 6.8% |
净利率FIHLRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 20.0% | 6.7% | ||
| Q2 25 | 3.3% | 7.5% | ||
| Q1 25 | -6.5% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 14.7% | 13.8% | ||
| Q2 24 | 9.9% | 8.0% | ||
| Q1 24 | 15.6% | 4.0% |
每股收益（稀释后）FIHLRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $1.24 | $0.40 | ||
| Q2 25 | $0.18 | $0.46 | ||
| Q1 25 | $-0.38 | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | $0.88 | $0.77 | ||
| Q2 24 | $0.46 | $0.45 | ||
| Q1 24 | $0.69 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $892.5M | $919.9M |
| 总债务越低越好 | $842.9M | — |
| 股东权益账面价值 | $2.4B | $7.3B |
| 总资产 | $12.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.35× | — |
8季度趋势，按日历期对齐
现金及短期投资FIHLRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $892.5M | $931.4M | ||
| Q2 25 | $919.4M | $991.8M | ||
| Q1 25 | $733.4M | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $806.8M | $1.2B | ||
| Q2 24 | $628.6M | $2.0B | ||
| Q1 24 | $671.7M | $1.7B |
总债务FIHLRVTY
| Q4 25 | — | — | ||
| Q3 25 | $842.9M | — | ||
| Q2 25 | $842.6M | — | ||
| Q1 25 | $449.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $448.8M | — | ||
| Q2 24 | $448.6M | — | ||
| Q1 24 | $448.4M | — |
股东权益FIHLRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $2.4B | $7.4B | ||
| Q2 25 | $2.3B | $7.6B | ||
| Q1 25 | $2.4B | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | $2.6B | $7.9B | ||
| Q2 24 | $2.5B | $7.9B | ||
| Q1 24 | $2.5B | $7.8B |
总资产FIHLRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $12.5B | $12.1B | ||
| Q2 25 | $13.0B | $12.4B | ||
| Q1 25 | $12.8B | $12.4B | ||
| Q4 24 | — | $12.4B | ||
| Q3 24 | $11.7B | $12.8B | ||
| Q2 24 | $11.9B | $13.4B | ||
| Q1 24 | $11.3B | $13.4B |
负债/权益比FIHLRVTY
| Q4 25 | — | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.19× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.17× | — | ||
| Q2 24 | 0.18× | — | ||
| Q1 24 | 0.18× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $155.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $154.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 23.7% | 21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.19× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-320.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流FIHLRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $155.2M | $138.5M | ||
| Q2 25 | $-359.2M | $134.3M | ||
| Q1 25 | $-433.1M | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | $318.9M | $147.9M | ||
| Q2 24 | $208.5M | $158.6M | ||
| Q1 24 | $-35.3M | $147.6M |
自由现金流FIHLRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $154.6M | $120.0M | ||
| Q2 25 | $-359.3M | $115.5M | ||
| Q1 25 | $-433.4M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | $317.2M | $125.6M | ||
| Q2 24 | $206.6M | $136.6M | ||
| Q1 24 | $-35.6M | $129.7M |
自由现金流率FIHLRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 23.7% | 17.2% | ||
| Q2 25 | -61.0% | 16.0% | ||
| Q1 25 | -65.8% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | 46.2% | 18.4% | ||
| Q2 24 | 38.3% | 19.7% | ||
| Q1 24 | -6.8% | 20.0% |
资本支出强度FIHLRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 0.1% | 2.6% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.0% | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | 0.2% | 3.3% | ||
| Q2 24 | 0.4% | 3.2% | ||
| Q1 24 | 0.1% | 2.7% |
现金转化率FIHLRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 1.19× | 2.97× | ||
| Q2 25 | -18.23× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 3.17× | 1.57× | ||
| Q2 24 | 3.88× | 2.87× | ||
| Q1 24 | -0.43× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FIHL
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
